DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Rhea-AI Summary

Daxor (NASDAQ: DXR), the global leader in blood volume measurement technology, will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference from October 17-19, 2024, in Aurora, CO. This elite conference unites cardiovascular thought-leaders to transform care and introduce innovative solutions.

Daxor's CEO, Michael Feldschuh, emphasized the opportunity to showcase their BVA-100™ Blood Volume Diagnostic, which addresses key challenges in cardiovascular care. Peer-reviewed studies have shown that BVA-guided care significantly improves patient outcomes, including:

• 82% reduction in 30-day mortality
• 86% reduction in 1-year mortality
• 56% reduction in 30-day readmissions
• 57% reduction in length of stay when performed upon admission

The BVA technology provides 98% accurate, actionable data for optimizing treatment plans and individualizing care, ultimately improving outcomes while reducing duration and cost.

Positive

• BVA-guided care shown to reduce 30-day mortality by 82% and 1-year mortality by 86%
• 56% reduction in 30-day hospital readmissions with BVA technology
• 57% reduction in length of stay when BVA is performed upon admission
• BVA technology provides 98% accurate, actionable data for treatment optimization
• Participation in MedAxiom CV Transforum Fall'24 Conference increases exposure to cardiovascular leaders

Negative

• None.

Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence

Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting cardiovascular thought-leaders from across the country to transform cardiovascular care together with leading industry innovators.

“We look forward to engaging with industry leaders at this pivotal gathering, connecting with top cardiovascular innovators to demonstrate how our blood volume analysis technology directly tackles key challenges: hospital readmissions, mortality rates, and resource optimization. MedAxiom's reputation for introducing outcome-improving, cost-reducing solutions makes this the ideal platform to highlight our technology," said Michael Feldschuh, Daxor's CEO and President.

BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes, including reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and also results in a 57% reduction in length of stay when performed upon admission (P<0.001). BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost.

View the Daxor Industry Partner Page.

About Daxor Corporation

Daxor Corporation (NASDAQ: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What are the key benefits of Daxor's BVA-100™ Blood Volume Diagnostic according to the press release?

According to the press release, Daxor's BVA-100™ Blood Volume Diagnostic has shown significant benefits in peer-reviewed studies, including an 82% reduction in 30-day mortality, 86% reduction in 1-year mortality, 56% reduction in 30-day readmissions, and a 57% reduction in length of stay when performed upon admission. The technology provides 98% accurate, actionable data for optimizing treatment plans and individualizing care.

When and where is Daxor (DXR) exhibiting its BVA-100™ technology in October 2024?

Daxor (DXR) will be exhibiting its BVA-100™ technology at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference, held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, from October 17-19, 2024.

How does Daxor's BVA technology impact hospital readmissions and length of stay?

According to the press release, Daxor's BVA technology has been shown to reduce 30-day hospital readmissions by 56% and decrease length of stay by 57% when performed upon admission, as demonstrated in peer-reviewed studies.

What is the accuracy rate of Daxor's BVA technology for blood volume measurement?

The press release states that Daxor's BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care for patients.